Abstract
It is unclear if current pricing and reimbursement policies adequately capture the incremental value of individual indications for multi-indication products. This study aims to map the launch sequence of multi-indication products across seven countries and compares indications in terms of quality of clinical evidence, regulatory approval timelines and HTA approval timelines.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call